Sinovac's sIPV shows positive data in late-stage polio study - Seeking Alpha

Sinovac's sIPV shows positive data in late-stage polio study - Seeking Alpha

Sinovac's sIPV shows positive data in late-stage polio study - Seeking Alpha

Posted: 16 Apr 2019 12:00 AM PDT

[unable to retrieve full-text content]Sinovac's sIPV shows positive data in late-stage polio study  Seeking Alpha

Sinovac Biotech (SVA) announces that the positive results from the it's Phase III clinical study of a Sabin strain-based inactivated polio vaccine (sIPV) w.

Oral Polio Vaccine (Opv) Market 2019 – Beijing Tiantan Biological, Pfizer, Merck & Co, GlaxoSmithKline, Sanofi - Market Trends

Posted: 29 Apr 2019 12:23 AM PDT

Report represents a comprehensive study of the Oral Polio Vaccine (Opv) Market. It consists of growth rate for the forecast period. The global report sums up by providing the estimated development of Oral Polio Vaccine (Opv) market in near future. It also involves driving factors that boosts the market. Besides, it includes competitive players in the market along with their market share.

Some of the major players involved in the market are:
Beijing Tiantan Biological
Pfizer
Merck & Co
GlaxoSmithKline
Sanofi

Market is broadly fragmented on the basis of application segments, product types and geographic boundaries. Each and every segment is mentioned in detail along with their growth during the forecast period.

Get Free Sample Copy of Report Here : https://www.glamresearch.com/report/global-oral-polio-vaccine-opv-market-by-product-30293/#sample

Report helps in providing data related to the key players in the market along with their revenue segmentation, business summary, and products. Additionally, it encompasses key product categories and segments including their sub-segments (if any) and applications. Report also comprises SWOT analysis of key players.

Global Oral Polio Vaccine (Opv) Market: Type Segment Analysis
Type 1
Type 2
Type 3
Type 4
Type 5

Global Oral Polio Vaccine (Opv) Market: Applications Segment Analysis
Application 1
Application 2
Application 3
Application 4
Application 5

Report projects a brief summary of Oral Polio Vaccine (Opv) market highlights the key features and statistics from the organization for the assessment of the growth of the related segment. Moreover, on the basis of geographical boundaries, market is classified into: Europe, Asia Pacific, Latin America, North America, and Middle East & Africa.

Objectives:
• Primary objective of this report is to ensure its use to its users to understand complete scenario of Oral Polio Vaccine (Opv) market. It gives overall idea about the market in terms of segmentation, market potential, influential trends and the challenges that the market is facing
• To provide detailed description of key players and their marketing strategies followed by press releases and relevant documents so as to get competitive analysis market understanding
• To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
• To offer detailed profiles of key players with regional analysis and focus on key rising opportunities and challenges faced by this market
• To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

Inquiry Before Buying @ https://www.glamresearch.com/report/global-oral-polio-vaccine-opv-market-by-product-30293/#inquiry

Customization:
We provide customization according to the requirements of our client needs. Following are some of the options of our customized report:
Regional and Country-level analysis of Oral Polio Vaccine (Opv) report by end use.

Thanks for reading this article.

Polio Eradication Loses Ground During 2019 - PrecisionVaccinations

Posted: 12 Apr 2019 12:00 AM PDT

There is some good news regarding polio vaccine research, just in time to reverse the negative trend during 2019. 

A new study found the Sabin strain–based Inactivated Polio Vaccine (sIPV) demonstrated an immunogenicity profile non-inferior to that of the conventional Inactivated Polio Vaccine (IPV), and it displayed a good safety profile.   

This phase 3 clinical trial found seroconversion rates in the sIPV and IPV groups were 98% and 94.1%, respectively, for type 1 poliovirus; and 98.9% and 97.7%, respectively, for type 3. 

This study is good news since the World Health Organization (WHO) encourages the development of new IPVs that use less virulent strains, such as the sIPV, which carries a lower bio-safety risk and demonstrates long-term affordability and accessibility. 

This is important news since the polio virus is being reported in various countries during 2019. 

As of April 10, 2019, the Global Polio Eradication Initiative report said there have been 13 total polio cases during 2019, segmented between 9 Wild Poliovirus (WPV) and 4 Vaccine-Derived Poliovirus (VDPV) cases. 

Polio is caused by the poliovirus, which spreads from person to person, by drinking water or eating food that is contaminated with infected feces, says the WHO. 

The WHO says there are 2 types of vaccines developed to stop polio transmission: oral polio vaccine (OPV) and inactivated polio vaccine. 

Both types of vaccine are necessary to eliminate polio. 

On the one hand, OPV is extremely effective in protecting both the individual and the community from infecting wild polioviruses.   

Sponsored Links:

However, because OPV is composed of a live attenuated vaccine virus, it may result in vaccine-derived poliovirus (VDPV) emergence or vaccine-associated paralytic polio (VAPP) on rare occasions.   

On the other hand, IPV carries no risk of VDPV emergence or VAPP because it contains no live virus, but IPV cannot stop the spread of poliovirus in a community, because when a person immunized with IPV is infected with WPV, the virus may still replicate in the gut and could spread to infect others.   

Based on these features, the WHO has suggested that OPV must be withdrawn soon after the end of WPV transmission, to prevent VAPP emergence and VDPV, and that, during the interim, IPV should be used to maintain population immunity levels, to sustain a polio-free world. 

To alert USA citizens which countries are reporting polio during 2019, the Centers for Disease Control and Prevention (CDC) have issued various Travel Alerts, which recommend that all travelers to these countries be fully vaccinated against polio. 

The CDC says adults who completed their routine polio vaccine series as children should receive a single, lifetime adult booster dose of the polio vaccine.     

Besides the polio vaccination, the CDC suggests you are up-to-date on several Routine Vaccines before visiting most of these countries. 

Pre-trip, vaccine and medication counseling appointments can be scheduled at Vax-Before-Travel.

Updated Vaccination Schedules, CDC Price List, Report Vaccine side effects, Travel Alerts

Comments

Post a Comment

Popular posts from this blog

Roseola vs. measles rash: What is the difference? - Medical News Today

Image
Roseola and measles are two different diseases that present with a high fever and a rash. They are both most commonly seen in childhood, although measles can affect people of any age, and roseola in adults is very rare. While both diseases share similarities, there are distinguishing factors, such as how the symptoms present and the disease progression. Read on to find out the difference between roseola and measles rashes. Roseola, also known as roseola infantum, sixth disease, or exanthema subitum, is a viral infection that typically affects children. The human herpesvirus 6 (HHV-6) or human herpesvirus 7 (HHV-7) causes roseola. The disease is spread through tiny respiratory droplets that people either breathe in or pick up from surfaces they touch. This disease usually presents in children between the ages of 6–12 months . Children who have this disease experience a high fever, followed by a pink or red rash. Roseola is a self-limiting viral illness, meaning it will typically go awa...
Read more

poliomyelitis treatment

Image
poliomyelitis treatment Drug and Device News March 2019 - P&T Community Posted: 04 Mar 2019 10:35 AM PST NEW DRUG APPROVALS Ontruzant, a Herceptin Biosimilar The FDA has approved trastuzumabdttb (Ontruzant, Samsung Bioepis Company, Ltd.) for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Trastuzumabdttb, a HER2/neu receptor antagonist, is the third FDA-approved biosimilar of Herceptin (Genentech). Patients should be selected for therapy based on an FDA-approved companion diagnostic. Trastuzumab-dttb carries a boxed warning about the risks of cardiomyopathy, serious and fatal infusion reactions, embryo-fetal toxicity, and pulmonary toxicity. Ontruzant will be marketed and distributed in the U.S. by Merck. Sources: Samsung Bioepis, January 21, 2019; Ontruzant . prescribing information, January 2019; FDA, January 18, 2019 Vaxelis, a Combination Vaccine T...
Read more

Managing Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction: A Scientific Statement From the American Heart Association

Image
causes of precapillary pulmonary hypertension :: Article Creator Long-term Oxygen Therapy Improves Exercise Capacity In PH Long-term oxygen improves exercise capacity in people with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH), a study suggests. Twelve weeks of supplemental oxygen led to a significant and clinically relevant improvements in exercise capacity, as assessed with the six-minute walking distance test (6MWD), by 42 meters (about 138 feet) over the distances walked at start of the study, "Long-term oxygen therapy in precapillary pulmonary hypertension — SOPHA study," which was published in Scientific Reports. PH is marked by high blood pressure in the pulmonary arteries, the blood vessels that transport blood from the heart to the lungs. Precapillary PH includes PAH, where blood pressure increases due to the narrowing of pulmonary arteries, along with CTEPH, a rare form of p...
Read more